Archivum Immunologiae et Therapiae Experimentalis最新文献_第10页

Lower BAFF Levels in Myasthenic Patients Treated with Glucocorticoids 糖皮质激素治疗的肌无力患者BAFF水平降低

IF 3.2 4区医学

Archivum Immunologiae et Therapiae Experimentalis Pub Date : 2021-08-02 DOI: 10.1007/s00005-021-00626-5

Ewa Sobieszczuk, Piotr Szczudlik, Justyna Kubiszewska, Beata Szyluk, Marta Lipowska, Małgorzata Dutkiewicz, Anna Kostera-Pruszczyk

{"title":"Lower BAFF Levels in Myasthenic Patients Treated with Glucocorticoids","authors":"Ewa Sobieszczuk, Piotr Szczudlik, Justyna Kubiszewska, Beata Szyluk, Marta Lipowska, Małgorzata Dutkiewicz, Anna Kostera-Pruszczyk","doi":"10.1007/s00005-021-00626-5","DOIUrl":"10.1007/s00005-021-00626-5","url":null,"abstract":"<div><p>B-cell activating factor (BAFF), a member of tumor necrosis factor family, activates B cells, promotes their survival and proliferation. BAFF is considered to have an influence on development of autoimmune diseases including myasthenia gravis (MG). We aimed to evaluate BAFF serum levels in MG patients, their potential connection with therapy and course of MG. Cross-sectional study. Two hundred eighteen adult patients with MG (67% women, age: 18–89 years, 82.6% AChR antibody seropositive (AChRAb(+)). Serum BAFF levels, their relationship with severity of clinical symptoms, therapy conducted, clinical and demographic features and other factors were analyzed. Patients with AChRAb(+) MG demonstrated significantly higher BAFF levels than MuSK-MG patients (831.2 ± 285.4 pg/ml vs. 745.6 ± 633.4 pg/ml, respectively; <i>p</i> = 0.030). Serum BAFF levels in women were significantly higher than in men (855.9 ± 302.5 vs. 756.6 ± 289.4, respectively; <i>p</i> = 0.017). Mean serum BAFF level was significantly decreased in patients who were ever treated with corticosteroids (CS) (770.4 ± 327.8 pg/ml vs. 891.3 ± 246.1 pg/ml, respectively; <i>p</i> = 0.001). Thymoma-MG patients demonstrated significantly lower BAFF levels (671.2 ± 244.9 vs. 833.5 ± 302.4, respectively; <i>p</i> = 0.044). Thymectomized patients did not differ in BAFF levels from the MG patients who had not undergone thymectomy. In multiple linear regression model, recent CS therapy and male sex were found to be independent predictors of lower BAFF levels. Serum BAFF level is decreased in patients treated with CS, which may suggest inhibiting influence of CS on BAFF—a potential mechanism contributing to the effectiveness of such therapy.</p></div>","PeriodicalId":8389,"journal":{"name":"Archivum Immunologiae et Therapiae Experimentalis","volume":"69 1","pages":""},"PeriodicalIF":3.2,"publicationDate":"2021-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s00005-021-00626-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39275887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Stimulation of Innate and Adaptive Immune Cells with Graphene Oxide and Reduced Graphene Oxide Affect Cancer Progression 用氧化石墨烯和还原氧化石墨烯刺激先天和适应性免疫细胞影响癌症进展

IF 3.2 4区医学

Archivum Immunologiae et Therapiae Experimentalis Pub Date : 2021-07-29 DOI: 10.1007/s00005-021-00625-6

Muhammad Amir Yunus, Muhammad Mahyiddin Ramli, Nurul Huda Osman, Rafeezul Mohamed

引用次数: 7

Anti-ANX A1 Antibody Therapy in MRL/lpr Murine Model of Systemic Lupus Erythematosus 抗anx A1抗体治疗系统性红斑狼疮MRL/lpr小鼠模型

IF 3.2 4区医学

Archivum Immunologiae et Therapiae Experimentalis Pub Date : 2021-07-28 DOI: 10.1007/s00005-021-00624-7

Silvya Bradyanova, Nikolina Mihaylova, Petroslav Chipinski, Yordan Manassiev, Melinda Herbáth, Dobroslav Kyurkchiev, József Prechl, Andrey I. Tchorbanov

{"title":"Anti-ANX A1 Antibody Therapy in MRL/lpr Murine Model of Systemic Lupus Erythematosus","authors":"Silvya Bradyanova, Nikolina Mihaylova, Petroslav Chipinski, Yordan Manassiev, Melinda Herbáth, Dobroslav Kyurkchiev, József Prechl, Andrey I. Tchorbanov","doi":"10.1007/s00005-021-00624-7","DOIUrl":"10.1007/s00005-021-00624-7","url":null,"abstract":"<div><p>Systemic lupus erythematosus (SLE) is a severe autoimmune disease characterized by dysfunction of immune regulation, overproduction of inflammatory cytokines and attack on normal tissues by self-reactive cells and antibodies. The main role in the pathogenesis plays the autoreactive tandem of B-T cells, responsible for lupus progression and acceleration. Both activated B and T cells express a phospholipid binding protein Annexin A1 and abnormal levels of the protein were found in murine and human autoimmune syndromes, potentiating its role as a therapeutic target. Here, using anti-annexin A1 antibody we explore its property to modulate the autoimmune response in MRL/lpr mouse model of lupus. Anti-ANX A1 antibody was tested in vitro using spleen cells from MRL/lpr mice to determine the effect on lymphocyte activation, plasma cells differentiation, apoptosis and proliferation by flow cytometry and ELISpot assays. Subsequently, several groups of young (disease-free) and old (sick) MRL/lpr mice were treated with the antibody to determine the levels of panel auto-antibodies and cytokines, T cell arrest and migration. Treatment of splenocytes with anti-ANX A1 antibody inhibited T-cell activation and proliferation, suppressed anti-dsDNA antibody-producing plasma cells and affected B cell apoptosis. Administration of the antibody to MRL/lpr mice resulted to decreased autoantibody levels to various lupus antigens, suppressed T cell migration from lymph nodes and increased the levels of IL4 mRNA compared to the control group. Anti-ANX A1 antibody therapy suppresses B and T cell over-activation and down- modulates disease activity.</p></div>","PeriodicalId":8389,"journal":{"name":"Archivum Immunologiae et Therapiae Experimentalis","volume":"69 1","pages":""},"PeriodicalIF":3.2,"publicationDate":"2021-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s00005-021-00624-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39254417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Changes in γδT Cells in Peripheral Blood of Patients with Ulcerative Colitis Exacerbations 溃疡性结肠炎加重患者外周血γδT细胞的变化

IF 3.2 4区医学

Archivum Immunologiae et Therapiae Experimentalis Pub Date : 2021-07-21 DOI: 10.1007/s00005-021-00620-x

Andrzej Gryglewski, Piotr Richter, Marian Szczepanik

{"title":"Changes in γδT Cells in Peripheral Blood of Patients with Ulcerative Colitis Exacerbations","authors":"Andrzej Gryglewski, Piotr Richter, Marian Szczepanik","doi":"10.1007/s00005-021-00620-x","DOIUrl":"10.1007/s00005-021-00620-x","url":null,"abstract":"<div><p>The role of γδT cells in ulcerative colitis (UC) is well confirmed in experimental animals and demonstrated in many clinical observations. Recent investigations have indicated that UC is associated with several forms of immune imbalance, such as an imbalance between effector T cells and regulatory T cells. However, little is known about the cellular aspect of clinical colitis exacerbations. We observed 140 patients with histologically confirmed UC over the course of 8 years. We investigated the percentage of γδT and αβT cells in peripheral blood of patients and also the expression of various surface markers (CD25, CD54, CD62L). Patients were assembled into stable colitis and exacerbated colitis groups. The percentage of γδT and αβT cells was evaluated by Ortho Cytorone Absolute flow cytometer. In patients with exacerbated colitis we observed a decrease of γδT cells in peripheral blood and an increased ratio of αβT/γδT. Additionally, we found that exacerbation results in a significant increase of percentage of γδTCD25, γδTCD54 and γδTCD62L lymphocytes in peripheral blood when compared to patients with stable colitis. Exacerbation of ulcerative colitis results in a decreased percentage of γδT cells in peripheral blood with increase of CD25, CD54 and CD62L expressing γδT cells. This may represent the effect of cell activation and migration, similar to that observed after the surgical trauma. We hope that this observation may help to predict exacerbations in colitis patients.</p></div>","PeriodicalId":8389,"journal":{"name":"Archivum Immunologiae et Therapiae Experimentalis","volume":"69 1","pages":""},"PeriodicalIF":3.2,"publicationDate":"2021-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s00005-021-00620-x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39204732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Post Transplantation Cyclophosphamide Improves Outcome of Autologous Hematopoietic Stem Cell Transplantation in Animal Model of Multiple Sclerosis 移植后环磷酰胺改善多发性硬化症动物模型自体造血干细胞移植的预后

IF 3.2 4区医学

Archivum Immunologiae et Therapiae Experimentalis Pub Date : 2021-06-28 DOI: 10.1007/s00005-021-00619-4

Kaja Kasarełło, Emilian Snarski, Dorota Sulejczak, Tomasz Ciesielski, Agnieszka Wiśniewska, Robert Wrzesień, Agnieszka Cudnoch-Jędrzejewska

{"title":"Post Transplantation Cyclophosphamide Improves Outcome of Autologous Hematopoietic Stem Cell Transplantation in Animal Model of Multiple Sclerosis","authors":"Kaja Kasarełło, Emilian Snarski, Dorota Sulejczak, Tomasz Ciesielski, Agnieszka Wiśniewska, Robert Wrzesień, Agnieszka Cudnoch-Jędrzejewska","doi":"10.1007/s00005-021-00619-4","DOIUrl":"10.1007/s00005-021-00619-4","url":null,"abstract":"<div><p>Experimental allergic encephalomyelitis (EAE) is the animal model of multiple sclerosis (MS). Autologous hematopoietic stem cell transplantation (AHSCT) has recently been recognized as the standard treatment for MS. The aim of our experiment was to investigate the effect of AHSCT with the addition of low-dose post-transplantation cyclophosphamide (Cy) on EAE in rats. Low dose post-transplantation Cy is used in haploidentical HSCT to reduce the risk of graft versus host disease. We hypothesized that it could bring additional benefit in autologous HSCT in autoimmune diseases. Rats with evoked EAE were treated with high dose (125 mg/kg) Cy, followed by AHSCT or high dose (125 mg/kg) Cy followed by AHSCT followed by low dose (20 mg/kg) Cy in two-time schedules—with the therapy applied during the pre-symptomatic or symptomatic phase of the disease. Both AHSCT and AHSCT with post-transplantation Cy in accordance with both time schedules reduce the intensity of the inflammatory response in the CNS, in comparison with non-treated EAE rats. The reduction of clinical symptoms was present in all AHSCT treatment protocols, however, it was significantly stronger when post-transplantation Cy was given during the symptomatic phase of the disease. AHSCT with the addition of post HSCT low dose Cy improved the results of AHSCT by not only reducing the intensity of inflammation in the CNS but also by significantly reducing the clinical symptoms in treated animals when compared to AHSCT alone. We provide an experimental rationale that the addition of post-transplantation Cy may improve the outcome of HSCT in MS.</p><h3>Graphic Abstract</h3>\u0000 <div><figure><div><div><picture><img></picture></div></div></figure></div>\u0000 </div>","PeriodicalId":8389,"journal":{"name":"Archivum Immunologiae et Therapiae Experimentalis","volume":"69 1","pages":""},"PeriodicalIF":3.2,"publicationDate":"2021-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s00005-021-00619-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39115246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

CTLA-4 Expression and Its Clinical Significance in Breast Cancer CTLA-4在乳腺癌中的表达及临床意义

IF 3.2 4区医学

Archivum Immunologiae et Therapiae Experimentalis Pub Date : 2021-06-20 DOI: 10.1007/s00005-021-00618-5

Rodrigo Kern, Carolina Panis

{"title":"CTLA-4 Expression and Its Clinical Significance in Breast Cancer","authors":"Rodrigo Kern, Carolina Panis","doi":"10.1007/s00005-021-00618-5","DOIUrl":"10.1007/s00005-021-00618-5","url":null,"abstract":"<div><p>Breast cancer is the leading cause of women’s death among all cancers. The main reason associated with this is the development of metastasis and therapy-resistant breast carcinoma (BC), which pose the main challenge of oncology nowadays. Evidence suggest that these tumors seem to have inhibitory mechanisms that may favor their progression and surveillance. Cancer cells can evade antitumor T cell responses by expressing some immune inhibitory molecules such as the cytotoxic T-lymphocyte antigen-4 (CTLA-4), whose clinical meaning has emerged in the last few years and is poorly understood in the BC context. This systematic literature review aims at identifying studies on CTLA-4 expression in BC, and address what is known about its clinical meaning. A literature search was performed in PubMed and LILACS databases, using the MESH terms “breast cancer”; “CTLA-4 Antigen/antagonists and inhibitors”; and “Lymphocytes, Tumor-Infiltrating/immunology”, published in the last 10 years. In total, 12 studies were included in this review. Systematic review used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Despite the small number of eligible studies, the literature reports some associations between CTLA-4 expression in the tumor microenvironment and worse BC outcomes, regardless of its molecular subtype<b>.</b> CTLA-4 expression in BC is a putative marker of clinical significance and a rationale therapeutic target in the emerging field of immunotherapy.</p></div>","PeriodicalId":8389,"journal":{"name":"Archivum Immunologiae et Therapiae Experimentalis","volume":"69 1","pages":""},"PeriodicalIF":3.2,"publicationDate":"2021-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s00005-021-00618-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39248273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 17

Osteopontin and Transplantation: Where Are We Now? 骨桥蛋白与移植:进展如何?

IF 3.2 4区医学

Archivum Immunologiae et Therapiae Experimentalis Pub Date : 2021-05-21 DOI: 10.1007/s00005-021-00617-6

Beata Kaleta

{"title":"Osteopontin and Transplantation: Where Are We Now?","authors":"Beata Kaleta","doi":"10.1007/s00005-021-00617-6","DOIUrl":"10.1007/s00005-021-00617-6","url":null,"abstract":"<div><p>Organ transplantation represents the optimal therapeutic tool for patients with end-stage organ failure. Hematopoietic stem cell transplantation (HSCT) is likewise an effective therapy for a wide range of malignant and non-malignant diseases. Better understanding of transplantation immunology and the use of multi-modal immunosuppression protocols, can decrease the risk of graft failure and graft-versus-host disease (GVHD) after HSCT. Nevertheless, a major challenge of modern transplantology still seems to be finding non-invasive biomarkers for recipients selection, monitoring of allograft function, and diagnosis of rejection. Since proinflammatory cytokine osteopontin (OPN) is closely involved in regulating both adaptive and innate immune responses, as well as the pathogenesis of inflammatory and autoimmune diseases, it is likely to play an important role in organ and HSC transplantation. This review is to summarize recent advances in our knowledge about OPN function in the kidney, heart, liver, lung, and HSC transplantation. Most studies found that elevated OPN is associated with poorer graft function in kidney, heart, liver and lung recipients. Moreover, some reports suggested that this protein can play role in GVHD pathogenesis. However, due to relatively small number of similar studies, as well as some inconclusive results, future investigation in this field is needed to verify if OPN can serve as a biomarker of organ and HSC transplantation. The knowledge about such markers will promote our understanding of the mechanisms underlying graft dysfunction and posttransplant mortality. In addition, such knowledge may be helpful in the development of new treatment strategies and identification of recipients with increased risk of allograft failure.</p></div>","PeriodicalId":8389,"journal":{"name":"Archivum Immunologiae et Therapiae Experimentalis","volume":"69 1","pages":""},"PeriodicalIF":3.2,"publicationDate":"2021-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s00005-021-00617-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39006007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Gut Microbiota Diversity in HIV-Infected Patients on Successful Antiretroviral Treatment is Linked to Sexual Preferences but not CD4 Nadir 成功接受抗逆转录病毒治疗的hiv感染者肠道微生物群多样性与性偏好有关，但与CD4最低点无关

IF 3.2 4区医学

Archivum Immunologiae et Therapiae Experimentalis Pub Date : 2021-05-13 DOI: 10.1007/s00005-021-00616-7

Elżbieta Jabłonowska, Joanna Strzelczyk, Anna Piekarska, Kamila Wójcik-Cichy

{"title":"Gut Microbiota Diversity in HIV-Infected Patients on Successful Antiretroviral Treatment is Linked to Sexual Preferences but not CD4 Nadir","authors":"Elżbieta Jabłonowska, Joanna Strzelczyk, Anna Piekarska, Kamila Wójcik-Cichy","doi":"10.1007/s00005-021-00616-7","DOIUrl":"10.1007/s00005-021-00616-7","url":null,"abstract":"<div><p>The effects of HIV infection and antiretroviral therapy (ART) on the gut microbiome are poorly understood and the literature data are inconsistent. The aim of this study was to assess the alpha and beta diversity of the fecal microbiota in HIV-infected patients on successful antiretroviral therapy with regard to sexual preferences and CD4 nadir. Thirty-six HIV-infected ART-treated patients with HIV viremia below 20 copies/ml and CD4 > 500 cells/μl were divided into two subgroups based on CD4 nadir. The composition of the intestinal microbiota was assessed by 16SrRNA sequencing (MiSeq Illumina). The alpha and beta diversity were analyzed according to CD4 nadir count and sexual preference. Several alpha diversity indexes were significantly higher in the MSM group than in heterosexual patients. The alpha diversity did not differ significantly between patients with CD4 nadir > 500 cells/μl and CD4 nadir < 200 cells/μl. Beta diversity was also associated with sexual preference. A significant difference in Weighted Unifrac was observed between all MSM and all non-MSM participants (<i>p</i> = 0.001). The MSM group was more diverse and demonstrated greater distances in Weighted Unifrac than the non-MSM group. The relative abundance of the Prevotella enterotype was higher in the MSM than the non-MSM group. Sexual preferences demonstrated a stronger influence on alpha and beta diversity in HIV-infected patients following successful antiretroviral treatment than HIV infection itself. The observed lack of association between CD4 nadir and alpha and beta diversity may be caused by the restoration of the faecal microbiota following antiretroviral treatment.</p></div>","PeriodicalId":8389,"journal":{"name":"Archivum Immunologiae et Therapiae Experimentalis","volume":"69 1","pages":""},"PeriodicalIF":3.2,"publicationDate":"2021-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s00005-021-00616-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38977475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Donor Recipient Chimeric Cells Induce Chimerism and Extend Survival of Vascularized Composite Allografts 供体受体嵌合细胞诱导嵌合并延长血管化复合同种异体移植物的存活

IF 3.2 4区医学

Archivum Immunologiae et Therapiae Experimentalis Pub Date : 2021-05-10 DOI: 10.1007/s00005-021-00614-9

Joanna Cwykiel, Arkadiusz Jundzill, Aleksandra Klimczak, Maria Madajka-Niemeyer, Maria Siemionow

{"title":"Donor Recipient Chimeric Cells Induce Chimerism and Extend Survival of Vascularized Composite Allografts","authors":"Joanna Cwykiel, Arkadiusz Jundzill, Aleksandra Klimczak, Maria Madajka-Niemeyer, Maria Siemionow","doi":"10.1007/s00005-021-00614-9","DOIUrl":"10.1007/s00005-021-00614-9","url":null,"abstract":"<div><p>This study evaluated the efficacy of donor recipient chimeric cell (DRCC) therapy created by fusion of donor and recipient derived bone marrow cells (BMC) in chimerism and tolerance induction in a rat vascularized composite allograft (VCA) model. Twenty-four VCA (groin flaps) from MHC-mismatched ACI (RT1<sup>a</sup>) donors were transplanted to Lewis (RT1<sup>l</sup>) recipients. Rats were randomly divided into (<i>n</i> = 6/group): Group 1—untreated controls, Groups 2—7-day immunosuppression controls, Group 3—DRCC, and Group 4—DRCC with 7-day anti-αβTCR monoclonal antibody and cyclosporine A protocol. DRCC created by polyethylene glycol-mediated fusion of ACI and Lewis BMC were cultured and transplanted (2–4 × 10<sup>6</sup>) to VCA recipients via intraosseous delivery route. Flow cytometry assessed peripheral blood chimerism while fluorescent microscopy and PCR tested the presence of DRCC in the recipient’s blood, bone marrow (BM), and lymphoid organs at the study endpoint (VCA rejection). No complications were observed after DRCC intraosseous delivery. Group 4 presented the longest average VCA survival (79.3 ± 30.9 days) followed by Group 2 (53.3 ± 13.6 days), Group 3 (18 ± 7.5 days), and Group 1 (8.5 ± 1 days). The highest chimerism level was detected in Group 4 (57.9 ± 6.2%) at day 7 post-transplant. The chimerism declined at day 21 post-transplant and remained at 10% level during the entire follow-up period. Single dose of DRCC therapy induced long-term multilineage chimerism and extended VCA survival. DRCC introduces a novel concept of customized donor-recipient cell-based therapy supporting solid organ and VCA transplants.</p></div>","PeriodicalId":8389,"journal":{"name":"Archivum Immunologiae et Therapiae Experimentalis","volume":"69 1","pages":""},"PeriodicalIF":3.2,"publicationDate":"2021-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s00005-021-00614-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38977551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Neoantigen Cancer Vaccines: Real Opportunity or Another Illusion? 新抗原癌症疫苗:真正的机会还是另一种错觉?

IF 3.2 4区医学

Archivum Immunologiae et Therapiae Experimentalis Pub Date : 2021-04-28 DOI: 10.1007/s00005-021-00615-8

Karen Manoutcharian, Jesus Guzman Valle, Goar Gevorkian

{"title":"Neoantigen Cancer Vaccines: Real Opportunity or Another Illusion?","authors":"Karen Manoutcharian, Jesus Guzman Valle, Goar Gevorkian","doi":"10.1007/s00005-021-00615-8","DOIUrl":"10.1007/s00005-021-00615-8","url":null,"abstract":"<div><p>In this communication, we will analyze some important factors and immunological phenomena related to neoantigen cancer vaccines, with particular emphasis on recently published Phase I clinical trials. Several obstacles and issues are addressed that challenge the current paradigm and inquire if neoantigens, which are essentially single-use vaccine candidates, are legitimate targets to induce protective immune responses with regard to the evolving mutational landscape. We also share insights into the striking similarities between cancer and antigenically variable pathogens and suggest that any successful vaccine against either should demonstrate a similar property: efficient induction of a diverse pool of immune cells equipped to prevent immune escape. Hence, to confront antigenic variability directly, we have employed our innovative vaccine concept, Variable Epitope Libraries, composed of large combinatorial libraries of heavily mutated epitopes, as a “universal” vaccine platform. Collectively, we offer critical analyses on key issues, which ultimately reflect on the prospective clinical relevance of personalized neoantigen vaccines which is still undefined.</p></div>","PeriodicalId":8389,"journal":{"name":"Archivum Immunologiae et Therapiae Experimentalis","volume":"69 1","pages":""},"PeriodicalIF":3.2,"publicationDate":"2021-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s00005-021-00615-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38849246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3